2019
Complications associated with immunotherapy for brain metastases.
Tran TT, Jilaveanu LB, Omuro A, Chiang VL, Huttner A, Kluger HM. Complications associated with immunotherapy for brain metastases. Current Opinion In Neurology 2019, 32: 907-916. PMID: 31577604, PMCID: PMC7398556, DOI: 10.1097/wco.0000000000000756.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBrain NeoplasmsHumansImmunologic FactorsImmunotherapyNeoplasm MetastasisNeoplasm Recurrence, LocalNeurotoxicity SyndromesConceptsBrain metastasesNeurologic toxicityImmune therapyPhase 2 clinical trialCheckpoint inhibitor therapyImmune checkpoint inhibitorsMultiple phase 2 clinical trialsTreatment-related morbidityBrain metastatic diseaseSymptomatic edemaCheckpoint inhibitorsAdverse eventsDurable responsesMedian survivalMetastatic diseaseInhibitor therapyMore patientsIntracranial activityPatient groupRadiation necrosisClinical trialsTherapy trialsMultidisciplinary teamMetastasisPatients
2005
Delayed Neurotoxicity in Primary Central Nervous System Lymphoma
Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, DeAngelis LM, Abrey LE. Delayed Neurotoxicity in Primary Central Nervous System Lymphoma. JAMA Neurology 2005, 62: 1595-1600. PMID: 16216945, DOI: 10.1001/archneur.62.10.1595.Peer-Reviewed Original ResearchConceptsPrimary central nervous lymphomaPathophysiologic mechanismsPrimary central nervous system lymphomaMemorial Sloan-Kettering Cancer CenterTreatment-related toxic effectsCentral nervous system lymphomaDiffuse white matter diseaseAvailable autopsy dataProgressive subcortical dementiaMental status changesNervous system lymphomaDepartment of NeurologyWhite matter damagePotential risk factorsWhite matter diseaseFrontal-subcortical circuitsMicrovascular alterationsNeurologic deteriorationCumulative incidenceClinical courseImproved survivalRetrospective reviewSystem lymphomaClinical findingsSubcortical dementia